EUVIMEDEUVIMED entdecken
Metaanalyse

Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis

Manjeet K Goyal, Priyata Dutta, Matthew C Choy iD, Jeffrey A Berinstein, Syed A Hassan, Vishal Sharma iD, Vineet Ahuja iD, Elliot Berinstein, Christopher F D Li Wai Suen iD, Peter D R Higgins, Danny Con iD, Peter De Cruz und 1 weitere

Inflammatory Bowel Diseases · 01.07.2026 · 32 (7) · 1344-1353

DOI: 10.1093/ibd/izag042 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 24.04.2026. Verfasst von Manjeet K Goyal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110029, India. Hauptthemen laut MEDLINE: Infliximab, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Health and Medical Research Council (NHMRC), NHMRC Postgraduate scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The optimal infliximab (IFX) dosing strategy for acute severe ulcerative colitis (ASUC) remains unclear. Though intensified IFX dosing is frequently employed, evidence supporting its efficacy has been mixed and it is uncertain if intensified IFX more effectively captures remission than standard-dose IFX. We conducted an updated meta-analysis comparing standard- vs intensified-dose IFX in ASUC, incorporating PREDICT-UC trial data and applying a Bayesian framework to better integrate prior evidence and quantify uncertainty.

Methods

Electronic databases were systematically searched from inception to December 2024 (PROSPERO ID: CRD42024616359). We conducted a 2-step meta-analysis. First, retrospective cohort studies were assessed with a frequentist random-effects meta-analytic approach. Second, because there is only 1 trial (PREDICT-UC) comparing intensified vs standard IFX in ASUC, we applied a Bayesian meta-analytic approach by using historical trials of standard-dose IFX in ASUC to define the prior probability distribution and then compared that to PREDICT-UC.

Results

Ten retrospective cohort studies (530 standard-dose and 406 intensified-dose patients) were included in the frequentist analysis. We applied a Bayesian binomial regression model with the historical randomized controlled trials of standard-dose IFX as the reference group. The estimated 3-month colectomy rate for standard-dose IFX was 27% (95% credible interval, 22%-33%). In the PREDICT-UC trial, observed colectomy rates were 15% in patients receiving rescue-dose IFX at 5 mg/kg and 6% in those receiving upfront intensified dosing at 10 mg/kg. Posterior estimates for both intensified dosing strategies in PREDICT-UC were credibly lower than the standard-dose IFX reference.

Conclusion

Integrating observational and trial data via Bayesian methods suggests that intensified IFX dosing reduces early colectomy in ASUC. These findings support prospective, adequately powered trials to confirm benefit, identify subgroups most likely to respond, and refine individualized accelerated-dosing algorithms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabColitis, UlcerativeGastrointestinal AgentsHumansBayes TheoremDose-Response Relationship, DrugRetrospective StudiesAcute DiseaseSeverity of Illness Index

Stichwörter der Autor:innen

acute severe ulcerative colitisadaptive dosingcolectomy ratesinfliximabintensified dosingmeta-analysisstandard dosing

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Department of Internal Medicine, Trinity Health, St. Joseph Mercy Ann Arbor, Ann Arbor, MI 48197, United States.
  • Department of Gastroenterology, Austin Health, Melbourne, Victoria, 3084, Australia.
  • Department of Medicine, The University of Melbourne, Austin Health, Melbourne, Victoria, 3084, Australia.
  • Divison of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, 48109, United States.
  • Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.

ORCID-Profile: Matthew C Choy, Vishal Sharma, Vineet Ahuja, Christopher F D Li Wai Suen, Danny Con, Shrinivas Bishu

Förderung

  • NIDDK NIH HHS
  • National Health and Medical Research Council (NHMRC)
  • NHMRC Postgraduate scholarship
  • NHMRC Emerging Leader 2 Fellowship
  • Janssen and Gandel Philanthropy

Zitieren

APA

Goyal, M. K., Dutta, P., Choy, M. C., Berinstein, J. A., Hassan, S. A., Sharma, V., Ahuja, V., Berinstein, E., Li Wai Suen, C. F. D., Higgins, P. D. R., Con, D., Cruz, P., & Bishu, S. (2026). Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis. Inflammatory Bowel Diseases, 32(7), 1344-1353. https://doi.org/10.1093/ibd/izag042

Vancouver

Goyal MK, Dutta P, Choy MC, Berinstein JA, Hassan SA, Sharma V, et al. Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis. Inflammatory Bowel Diseases. 2026;32(7):1344-1353. doi:10.1093/ibd/izag042

BibTeX
@article{Goyal2026,
  author = {Goyal, Manjeet K and Dutta, Priyata and Choy, Matthew C and Berinstein, Jeffrey A and Hassan, Syed A and Sharma, Vishal and Ahuja, Vineet and Berinstein, Elliot and Li Wai Suen, Christopher F D and Higgins, Peter D R and Con, Danny and Cruz, Peter De and Bishu, Shrinivas},
  title = {Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {7},
  pages = {1344--1353},
  doi = {10.1093/ibd/izag042}
}
Kostenlos starten →